Which patients receiving warfarin can be treated safely with a drug-eluting stent?
Conversely, stopping warfarin for up to a year and relying on dual antiplatelet therapy may not be sufficient to prevent the risk of disabling or fatal stroke. [...]the dilemma when managing these patients is a fine balance between the risks of in-stent restenosis, stent thrombosis, thromboembolism...
Gespeichert in:
| Veröffentlicht in: | Heart (British Cardiac Society) 2008-03, Vol.94 (3), p.275-277 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 277 |
|---|---|
| container_issue | 3 |
| container_start_page | 275 |
| container_title | Heart (British Cardiac Society) |
| container_volume | 94 |
| creator | Ryding, A D S Banning, A P |
| description | Conversely, stopping warfarin for up to a year and relying on dual antiplatelet therapy may not be sufficient to prevent the risk of disabling or fatal stroke. [...]the dilemma when managing these patients is a fine balance between the risks of in-stent restenosis, stent thrombosis, thromboembolism and bleeding complications. Since the CHADS2 and BRI scores share some common variables it follows that patients with AF at high risk of stroke are also likely to be at higher risk of bleeding. |
| doi_str_mv | 10.1136/hrt.2007.121459 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70293382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4020735431</sourcerecordid><originalsourceid>FETCH-LOGICAL-b380t-d2831048e504ed2f1278a8e8a75e7eb5d04973fad5684a41d03a2b99ec622ac83</originalsourceid><addsrcrecordid>eNqF0dtrFDEUBvAgiq3VZ98kIPogzDaXyWWeii7esCoUL30LZzJnullnZ9ckY-1_b5ZZKvjiUwL5nY_DF0Iec7bgXOrTVcwLwZhZcMFr1dwhx7zWthKMX94td6lUpZk0R-RBSmvGWN1YfZ8ccSuMtlwdk4vvq-BXdAc54JgTjegx_ArjFb2G2EMMI_Uw0hZpjggZO5qgx-GGXoe8okC7OF1VOEx5P5JyyTh7SO71MCR8dDhPyNc3r78s31Xnn9--X748r1ppWa46YSVntUXFauxEz4WxYNGCUWiwVV1Z1sgeOqVtDTXvmATRNg16LQR4K0_I8zl3F7c_J0zZbULyOAww4nZKzjDRSGlFgU__gevtFMeym-PGMt2IkljU6ax83KYUsXe7GDYQbxxnbl-2K2W7fdluLrtMPDnkTu0Gu7_-0G4Bzw4AkoehjzD6kG5d-SUhmdm7anahNPj79h3iD6eNNMp9-rZ0Hy4uhaj1K_ex-Bezbzfr_275B1jcopY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780692622</pqid></control><display><type>article</type><title>Which patients receiving warfarin can be treated safely with a drug-eluting stent?</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Ryding, A D S ; Banning, A P</creator><creatorcontrib>Ryding, A D S ; Banning, A P</creatorcontrib><description>Conversely, stopping warfarin for up to a year and relying on dual antiplatelet therapy may not be sufficient to prevent the risk of disabling or fatal stroke. [...]the dilemma when managing these patients is a fine balance between the risks of in-stent restenosis, stent thrombosis, thromboembolism and bleeding complications. Since the CHADS2 and BRI scores share some common variables it follows that patients with AF at high risk of stroke are also likely to be at higher risk of bleeding.</description><identifier>ISSN: 1355-6037</identifier><identifier>EISSN: 1468-201X</identifier><identifier>DOI: 10.1136/hrt.2007.121459</identifier><identifier>PMID: 18276815</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Cardiovascular Society</publisher><subject><![CDATA[Aged ; Angina pectoris ; Angioplasty, Balloon, Coronary - adverse effects ; Anticoagulants - administration & dosage ; Aspirin ; Aspirin - administration & dosage ; Biological and medical sciences ; Cardiology. Vascular system ; Coronary Restenosis - prevention & control ; Coronary Restenosis - therapy ; Coronary Thrombosis - etiology ; Coronary Thrombosis - prevention & control ; Coronary Thrombosis - therapy ; Diabetes ; Drug-Eluting Stents ; Heart attacks ; Humans ; Medical sciences ; Middle Aged ; Patients ; Platelet Aggregation Inhibitors - administration & dosage ; Postoperative Hemorrhage - etiology ; Postoperative Hemorrhage - prevention & control ; Prostheses ; Stents ; Stroke ; Stroke - prevention & control ; Thromboembolism ; Thrombosis ; Ticlopidine - administration & dosage ; Ticlopidine - analogs & derivatives ; Warfarin - administration & dosage]]></subject><ispartof>Heart (British Cardiac Society), 2008-03, Vol.94 (3), p.275-277</ispartof><rights>2008 BMJ Publishing Group and British Cardiac Society</rights><rights>2008 INIST-CNRS</rights><rights>Copyright: 2008 2008 BMJ Publishing Group and British Cardiac Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://heart.bmj.com/content/94/3/275.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://heart.bmj.com/content/94/3/275.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77343,77374</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20123075$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18276815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ryding, A D S</creatorcontrib><creatorcontrib>Banning, A P</creatorcontrib><title>Which patients receiving warfarin can be treated safely with a drug-eluting stent?</title><title>Heart (British Cardiac Society)</title><addtitle>Heart</addtitle><description>Conversely, stopping warfarin for up to a year and relying on dual antiplatelet therapy may not be sufficient to prevent the risk of disabling or fatal stroke. [...]the dilemma when managing these patients is a fine balance between the risks of in-stent restenosis, stent thrombosis, thromboembolism and bleeding complications. Since the CHADS2 and BRI scores share some common variables it follows that patients with AF at high risk of stroke are also likely to be at higher risk of bleeding.</description><subject>Aged</subject><subject>Angina pectoris</subject><subject>Angioplasty, Balloon, Coronary - adverse effects</subject><subject>Anticoagulants - administration & dosage</subject><subject>Aspirin</subject><subject>Aspirin - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Coronary Restenosis - prevention & control</subject><subject>Coronary Restenosis - therapy</subject><subject>Coronary Thrombosis - etiology</subject><subject>Coronary Thrombosis - prevention & control</subject><subject>Coronary Thrombosis - therapy</subject><subject>Diabetes</subject><subject>Drug-Eluting Stents</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Postoperative Hemorrhage - etiology</subject><subject>Postoperative Hemorrhage - prevention & control</subject><subject>Prostheses</subject><subject>Stents</subject><subject>Stroke</subject><subject>Stroke - prevention & control</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Ticlopidine - administration & dosage</subject><subject>Ticlopidine - analogs & derivatives</subject><subject>Warfarin - administration & dosage</subject><issn>1355-6037</issn><issn>1468-201X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0dtrFDEUBvAgiq3VZ98kIPogzDaXyWWeii7esCoUL30LZzJnullnZ9ckY-1_b5ZZKvjiUwL5nY_DF0Iec7bgXOrTVcwLwZhZcMFr1dwhx7zWthKMX94td6lUpZk0R-RBSmvGWN1YfZ8ccSuMtlwdk4vvq-BXdAc54JgTjegx_ArjFb2G2EMMI_Uw0hZpjggZO5qgx-GGXoe8okC7OF1VOEx5P5JyyTh7SO71MCR8dDhPyNc3r78s31Xnn9--X748r1ppWa46YSVntUXFauxEz4WxYNGCUWiwVV1Z1sgeOqVtDTXvmATRNg16LQR4K0_I8zl3F7c_J0zZbULyOAww4nZKzjDRSGlFgU__gevtFMeym-PGMt2IkljU6ax83KYUsXe7GDYQbxxnbl-2K2W7fdluLrtMPDnkTu0Gu7_-0G4Bzw4AkoehjzD6kG5d-SUhmdm7anahNPj79h3iD6eNNMp9-rZ0Hy4uhaj1K_ex-Bezbzfr_275B1jcopY</recordid><startdate>20080301</startdate><enddate>20080301</enddate><creator>Ryding, A D S</creator><creator>Banning, A P</creator><general>BMJ Publishing Group Ltd and British Cardiovascular Society</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20080301</creationdate><title>Which patients receiving warfarin can be treated safely with a drug-eluting stent?</title><author>Ryding, A D S ; Banning, A P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b380t-d2831048e504ed2f1278a8e8a75e7eb5d04973fad5684a41d03a2b99ec622ac83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Angina pectoris</topic><topic>Angioplasty, Balloon, Coronary - adverse effects</topic><topic>Anticoagulants - administration & dosage</topic><topic>Aspirin</topic><topic>Aspirin - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Coronary Restenosis - prevention & control</topic><topic>Coronary Restenosis - therapy</topic><topic>Coronary Thrombosis - etiology</topic><topic>Coronary Thrombosis - prevention & control</topic><topic>Coronary Thrombosis - therapy</topic><topic>Diabetes</topic><topic>Drug-Eluting Stents</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Postoperative Hemorrhage - etiology</topic><topic>Postoperative Hemorrhage - prevention & control</topic><topic>Prostheses</topic><topic>Stents</topic><topic>Stroke</topic><topic>Stroke - prevention & control</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Ticlopidine - administration & dosage</topic><topic>Ticlopidine - analogs & derivatives</topic><topic>Warfarin - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ryding, A D S</creatorcontrib><creatorcontrib>Banning, A P</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Heart (British Cardiac Society)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ryding, A D S</au><au>Banning, A P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Which patients receiving warfarin can be treated safely with a drug-eluting stent?</atitle><jtitle>Heart (British Cardiac Society)</jtitle><addtitle>Heart</addtitle><date>2008-03-01</date><risdate>2008</risdate><volume>94</volume><issue>3</issue><spage>275</spage><epage>277</epage><pages>275-277</pages><issn>1355-6037</issn><eissn>1468-201X</eissn><abstract>Conversely, stopping warfarin for up to a year and relying on dual antiplatelet therapy may not be sufficient to prevent the risk of disabling or fatal stroke. [...]the dilemma when managing these patients is a fine balance between the risks of in-stent restenosis, stent thrombosis, thromboembolism and bleeding complications. Since the CHADS2 and BRI scores share some common variables it follows that patients with AF at high risk of stroke are also likely to be at higher risk of bleeding.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Cardiovascular Society</pub><pmid>18276815</pmid><doi>10.1136/hrt.2007.121459</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-6037 |
| ispartof | Heart (British Cardiac Society), 2008-03, Vol.94 (3), p.275-277 |
| issn | 1355-6037 1468-201X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70293382 |
| source | MEDLINE; BMJ Journals - NESLi2; PubMed Central |
| subjects | Aged Angina pectoris Angioplasty, Balloon, Coronary - adverse effects Anticoagulants - administration & dosage Aspirin Aspirin - administration & dosage Biological and medical sciences Cardiology. Vascular system Coronary Restenosis - prevention & control Coronary Restenosis - therapy Coronary Thrombosis - etiology Coronary Thrombosis - prevention & control Coronary Thrombosis - therapy Diabetes Drug-Eluting Stents Heart attacks Humans Medical sciences Middle Aged Patients Platelet Aggregation Inhibitors - administration & dosage Postoperative Hemorrhage - etiology Postoperative Hemorrhage - prevention & control Prostheses Stents Stroke Stroke - prevention & control Thromboembolism Thrombosis Ticlopidine - administration & dosage Ticlopidine - analogs & derivatives Warfarin - administration & dosage |
| title | Which patients receiving warfarin can be treated safely with a drug-eluting stent? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T19%3A00%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Which%20patients%20receiving%20warfarin%20can%20be%20treated%20safely%20with%20a%20drug-eluting%20stent?&rft.jtitle=Heart%20(British%20Cardiac%20Society)&rft.au=Ryding,%20A%20D%20S&rft.date=2008-03-01&rft.volume=94&rft.issue=3&rft.spage=275&rft.epage=277&rft.pages=275-277&rft.issn=1355-6037&rft.eissn=1468-201X&rft_id=info:doi/10.1136/hrt.2007.121459&rft_dat=%3Cproquest_cross%3E4020735431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780692622&rft_id=info:pmid/18276815&rfr_iscdi=true |